The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Anti-cancer compound goes beyond current BTK inhibitors in CLL, other blood cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers have identified a next-generation BTK degrader that could help overcome treatment resistance in chronic lymphocytic leukemia and related blood cancers. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves Breyanzi CAR T-cell therapy in adults with R/R/ CLL or SLL

FDA has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor CAR T-cell therapy for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.  
Clinical Roundup

Imbruvica + venetoclax demonstrates efficacy and sustained response in older patients with previously untreated CLL

Four-year follow-up results from the phase III GLOW study showed that investigational, fixed-duration treatment with Imbruvica (ibrutinib) in combination with venetoclax reduced the risk of progression or death by 79% among older and/or unfit patients with previously untreated chronic lymphocytic leukemia compared to patients treated with chemoimmunotherapy. 
Clinical Roundup

Venclyxto/Venclexta combination shows sustained PFS in CLL after four years off treatment

Five-year follow-up results from the phase III CLL14 trial demonstrated that over 60% of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus Gazyva (obinutuzumab) continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account